Prognosis and serum creatinine levels in acute renal failure at the time of nephrology consultation: an observational cohort study

Jose Ramon Perez-Valdivieso* 1, Maira Bes-Rastrollo2, Pablo Monedero1, Jokin de Irala2 and Francisco Javier Lavilla3

Address: 1Department of Anesthesia and Critical Care, Clinica Universitaria, University of Navarra, Pamplona, Spain, 2Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain and 3Renal Unit, Clinica Universitaria de Navarra, University of Navarra, Pamplona, Spain

Email: Jose Ramon Perez-Valdivieso* - jrpvaldi@unav.es; Maira Bes-Rastrollo - mbes@unav.es; Pablo Monedero - pmonedero@unav.es; Jokin de Irala - jdeirala@unav.es; Francisco Javier Lavilla - jlavilla@unav.es

* Corresponding author

Abstract

Background: The aim of this study is to evaluate the association between acute serum creatinine changes in acute renal failure (ARF), before specialized treatment begins, and in-hospital mortality, recovery of renal function, and overall mortality at 6 months, on an equal degree of ARF severity, using the RIFLE criteria, and comorbid illnesses.

Methods: Prospective cohort study of 1008 consecutive patients who had been diagnosed as having ARF, and had been admitted in an university-affiliated hospital over 10 years. Demographic, clinical information and outcomes were measured. After that, 646 patients who had presented enough increment in serum creatinine to qualify for the RIFLE criteria were included for subsequent analysis. The population was divided into two groups using the median serum creatinine change (101%) as the cut-off value. Multivariate non-conditional logistic and linear regression models were used.

Results: A ≥ 101% increment of creatinine respect to its baseline before nephrology consultation was associated with significant increase of in-hospital mortality (35.6% vs. 22.6%, p < 0.001), with an adjusted odds ratio of 1.81 (95% CI: 1.08–3.03). Patients who required continuous renal replacement therapy in the ≥ 101% increment group presented a higher increase of in-hospital mortality (62.7% vs 46.4%, p = 0.048), with an adjusted odds ratio of 2.66 (95% CI: 1.00–7.21). Patients in the ≥ 101% increment group had a higher mean serum creatinine level with respect to their baseline level (114.72% vs. 37.96%) at hospital discharge. This was an adjusted 48.92% (95% CI: 13.05–84.79) more serum creatinine than in the < 101% increment group.

Conclusion: In this cohort, patients who had presented an increment in serum level of creatinine of ≥ 101% with respect to basal values, at the time of nephrology consultation, had increased mortality rates and were discharged from hospital with a more deteriorated renal function than those with similar Liano scoring and the same RIFLE classes, but with a < 101% increment. This finding may provide more information about the factors involved in the prognosis of ARF. Furthermore, the calculation of relative serum creatinine increase could be used as a practical tool to identify those patients at risk, and that would benefit from an intensive therapy.
Background

Acute renal failure (ARF) is a life threatening illness with a high mortality despite advances in supportive care [1-14]. Although there is a strong and direct relation between multiorgan failure and in-hospital mortality, severity of illness does not explain the variation in outcomes among patients with acute renal failure [5,9,10]. There is an increased cost in terms of patient prognosis, financial and clinical management. In a study, 30% of patients did not recover completely their renal function [15] and, in other studies, progression to chronic renal failure in many patients is suggested [9,16]. In regard to these concerns, prompt recognition and early consultation with a nephrologist have been postulated to improve the outcome of patients with acute renal failure [7,11,12,17]. Nevertheless, the published evidence is scarce.

The absence of a consensus definition of ARF has made research about ARF difficult [6,18,19]. Recently, the Acute Dialysis Quality Initiative (ADQI) published a uniformed definition called the RIFLE (Risk, Injury, Failure, Loss, End Stage) criteria [20]. The RIFLE criteria has been adopted by the Acute Kidney Injury Network (AKIN) [6].

Diagnosis of ARF based upon changes in serum creatinine may be delayed due to the fact that, in the non-steady-state conditions of ARF, as GFR falls creatinine secretion is increased [11]. Large changes in GFR are initially manifested as small quantitative changes in serum creatinine in the first 24–48 hours after renal injury [11]. After these one or two days, the degree of serum creatinine changes will reflect the change in GFR. Finally, the serum creatinine is stabilized, and that takes about 7 days [11,20]. Therefore, it is almost impossible to exactly determine the onset of the ARF; and also calculating the exact time elapsed until the nephrology consultation. However, measuring serum creatinine level is a practical approach for discovering short-term alteration in renal function, despite its limitations, because it is readily used in clinical practice and it is specific for renal function [20,21]. In patients with stable renal function, those levels are constant, with a daily variability of 8% [22,23], so increasing levels might suggest the first stage of ARF.

We conducted this study to identify and quantify a correlation between acute serum creatinine changes in ARF, measuring them at the time of nephrology consultation, and mortality and recovery of renal function. We hypothesized that, at the same levels of severity of renal and comorbid illnesses, the higher the acute serum creatinine reached with respect to its baseline, before the nephrologist first began to treat the patient, the worse the outcome will be.

Methods

Study population

The University Hospital of Navarra is a tertiary care academic teaching medical center with 400 beds in the city of Pamplona, Spain. After hospital ethics committee approval, a cohort of 1008 consecutive patients who had been diagnosed as having acute renal failure, and had been admitted in our hospital between 1996 and 2006, was prospectively entered in a computerized database. Explicit patient consent was not required by the hospital ethics committee due to the observational nature of the study, and because collecting the data was a part of our academical-hospital routine work. Patients’ anonymity was always strictly preserved. We restricted our analysis to patients who had enough increase of serum creatinine during their admission to fulfill the RIFLE criteria for ARF [20], and were older than 16 years. Three hundred and six patients did not fulfill the RIFLE serum creatinine criteria nor presented oliguria during their stay. Forty-nine patients presented oliguria, but did not have substantial increase of creatinine. Seven patients were younger than 16 years. Finally, 646 patients were included for subsequent analysis.

Definition of the variables

ARF was defined and diagnosed if patients had showed substantial increment in serum creatinine during their admission to qualify for the RIFLE criteria. After that, patients were classified to the maximum RIFLE class according to the peak creatinine (the highest) reached during their hospital stay. On the contrary, we could not collect full information for urine output, so we were not able to classify the patients by that RIFLE criteria. For patients without chronic renal failure reported, the baseline creatinine was calculated using the Modification of Diet in Renal Disease (MDRD) equation [24], as recommended by the ADQI workgroup [20], assuming a glomerular filtration rate of 75 ml/minute/1.73 m². For patients with a history of renal failure the baseline creatinine was defined as the one measured at hospital admission [4]. The term community-acquired ARF was used when the patient had presented ARF on admission to the hospital.

Demographic data, etiology of acute renal failure, comorbidity conditions, severity of illness, and laboratory data were all prospectively collected. The difference between serum creatinine value at time when nephrologist first saw the case and baseline value was calculated and expressed as a percentage: Creatinine change (%) = [(creatinine when nephrologist saw the case - basal creatinine)/basal creatinine] * 100. Severity of illness was measured through Liano score (0.032*age in decades - 0.086*male gender - 0.109*nephrotoxic + 0.109*oliguria + 0.116*hypotension + 0.122*jaundice + 0.150*coma -
In addition, linear regression models were used to assess the association between the increment of creatinine at time when nephrologists saw the case (exposure), and the recovery of renal function considering the increase in the percentage of creatinine at hospital discharge with respect to the baseline values (outcome). After excluding in-hospital dead patients, we estimated the regression coefficient and their 95% CI for the larger increment group compared to the lesser increment group considered as the reference category. This coefficient represents the absolute difference in creatinine increment at hospital discharge between the ≥101% increment group and the <101% increment group.

In both non-conditional logistic regression and linear regression, we fitted a crude model (univariate, i.e., without any adjustment), an age and gender model, and a multivariate-adjusted model including the following variables: Liano scoring, Karnofsky scoring, prior food intake, chronic renal failure, diabetes, treatment of acute renal failure, causes of acute renal failures, community-acquired acute renal failure, basal hemoglobin, basal serum albumin, and RIFLE classes selected by the descriptive univariate analysis of potential confounders with a p value less than 0.10. The Liano scoring includes in its equation the variables for nephrotoxicity, oliguria, hypotension, jaundice, mental status, and assisted respiration. Continuous variables were expressed as medians (and interquartile ranges), and compared using Mann-Whitney U test. Categorical variables were expressed as proportions and compared with the Chi-squared test. We evaluated all first-order multiplicative interactions (effect modifications) through product terms.

Overall survival at 6 months across groups was analyzed using the Kaplan-Meier methods, and differences between groups were tested using the log-rank test. The time of origin was the date when the nephrology consultation started. The event defined was death whereas those cases alive at the end of follow-up and those lost to follow-up were censored at their last observation.

All p values presented are two tailed, p < 0.05 was considered statistically significant. Statistical analyses were conducted using SPSS v.12.0.1 (SPSS Inc., Chicago, IL, USA).

Results
Six hundred and forty-six patients were evaluated, among them one hundred and eighty-eight died in-hospital. The demographics and baseline clinical characteristics are shown in Table 1. Subjects in the ≥101% increment of creatinine group were more likely to be female (p = 0.01), had impaired prior food intake (p = 0.02), and required more renal replacement therapy (p < 0.001). The ≥101% increment of creatinine group was associated with high
prevalence of community-acquired ARF (p = 0.02), and worse Karnofsky scoring (p = 0.015). The group with ≥ 101% increment of creatinine was also associated with higher Liano scoring at the time of nephrology consultation (p < 0.001), including higher prevalence of hypotension (p < 0.001), oliguria (p < 0.001), jaundice (p = 0.008), coma (p = 0.027), and were on mechanical ventilation (p = 0.002). RIFLE classes reached during the ARF were more severe in subjects in the ≥ 101% increment of

Table 1: Characteristics of patients, according to percentage of difference of creatinine* at nephrology consultation with respect to basal creatinine

| GROUPS OF % CREATININE INCREASE | < 101% increment | ≥ 101% increment | p value |
|---------------------------------|-----------------|-----------------|--------|
| N of patients                   | 323             | 323             |        |
| Increase of Creatinine, median % (IQR).  | 34.07 (66.67)   | 201.52 (149.22) | 0.36   |
| Age, median years (IQR).         | 63 (20)         | 62 (17)         | 0.01   |
| Male gender (%)                  | 74.3            | 65.0            | 0.01   |
| Surgical (%)                     | 24.9            | 24.2            | 0.565  |
| Oncology patients (%)            | 36.5            | 34.4            |        |
| Patients with no previous history of CRF (%) | 61.30   | 91.64          | < 0.001|
| Basal Serum Creatinine according to the MDRD equation, median (mg/dL) (IQR). | 1.04 (0.19)   | 1.04 (0.22)    | 0.25   |
| Patients with history of CRF (%)  | 38.70           | 8.36            | < 0.001|
| Basal Serum Creatinine for CRF patients, median mg/dL (IQR), | 2.3 (2.2) | 1.5 (0.6) | < 0.001|
| RIFLE criteria (%)               | Risk            | Injury          | Failure |
|                                 | 35.9            | 26.6            | 37.5   | 0.0    | 29.1   | 70.9   |
|                                 | Oliguria (%)     | 31.3            | 50.8   | < 0.001|
|                                 | Jaundice (%)     | 22.0            | 31.3   | 0.008  |
|                                 | Coma (%)         | 11.8            | 18.0   | 0.027  |
|                                 | Conciousness (%) | 80.8            | 76.8   | 0.211  |
|                                 | Mechanical ventilation (%) | 18.3 | 28.5 | 0.002  |
|                                 | Aminoglycoside use (%) | 12.7  | 17.0  | 0.121  |
|                                 | Radiocontrast procedures (%) | 19.5 | 20.7  | 0.695  |
|                                 | Diabetic (%)     | 11.1            | 6.5    | 0.037  |
|                                 | Nephrotoxicity (%) | 43.0 | 43.7  | 0.874  |
| Causes of Acute Renal Failure   | Pre-renal (%)    | 77.1            | 72.1   | 0.079  |
|                                 | Intrinsic renal (%) | 18.9 | 19.2 |        |
|                                 | Post-renal (%)   | 2.2             | 3.4    |        |
|                                 | Other causes (%) | 1.9             | 5.3    |        |
| Subsecuent Treatment of Acute Renal Failure | Non-Dialytic (%) | 75.5 | 61.0 | < 0.001|
|                                 | Continuous Replacement Therapy (%) | 11.1 | 22.6 |        |
|                                 | Both (Intermittent+Continuous) (%) | 6.2 | 8.7  |        |
| Prior food intake               | Optimal nutrition (%) | 37 | 24  | 0.024  |
|                                 | Light malnutrition (%) | 18.1 | 20.7 |        |
|                                 | Moderate malnutrition (%) | 23.9 | 30.9 |        |
|                                 | Severe malnutrition (%) | 21 | 24.4 |        |

*Creatinine change (%) = [(creatinine at nephrology consultation - Basal creatinine)/Basal creatinine] × 100 IQR: Interquartile range. CRF: Chronic Renal Failure. MDRD: Modification of Diet in Renal Disease
creatinine group (p < 0.001). There was a higher prevalence of diabetes (p = 0.037) in this group.

The ≥ 101% increment group was associated with significant increased total in-hospital mortality (35.6% vs. 22.6%, P < 0.001), with an adjusted odds ratio of 1.81 (95% CI: 1.08–3.03) (Table 2). Moreover, those patients in the ≥ 101% increment group who required continuous renal replacement therapy presented a higher increase of in-hospital mortality (62.7% vs 46.4%, P = 0.048), with an adjusted odds ratio of 2.66 (95% CI: 1.00–7.21) (Table 3). We noticed that patients in the ≥ 101% increment group had a higher mean serum creatinine level in comparison to their baseline level (114.72% vs. 37.96%) at hospital discharge (Table 4). In the ≥ 101% increment group, creatinine was an adjusted 48.92% (95% CI: 13.05–84.79) higher than the < 101% increment group.

The overall mortality rate was 337 deaths (52.2%) in 6 months. According to the Kaplan-Meier plot, the ≥ 101% increment group also had a statistically significant higher mortality rate in this period as compared with the < 101% increment group (Log Rank test = 0.012) (Figure 1). During the first 60 days of follow-up 175 deaths (27.1%) occurred.

### Table 2: Odds Ratios (ORs) and (95% confidence intervals) for in-hospital mortality; according to the increased percentage of creatinine with respect to basal creatinine

| GROUPS OF % CREATININE INCREASE | < 101% increment | ≥ 101% increment | p value |
|----------------------------------|------------------|------------------|---------|
| Creatinine and mortality n       | 323              | 323              |         |
| Incidence of in-hospital mortality, n (%) | 73 (22.6) | 115 (35.6) |         |
| Odds Ratios                      |                  |                  |         |
| Crude OR (95% CI)                | 1.00 (Ref.)      | 1.89 (1.34–2.68) | < 0.001 |
| Age- and sex-adjusted OR (95% CI)| 1.00 (Ref.)      | 1.91 (1.35–2.70) | < 0.001 |
| Multivariate-adjusted OR† (95% CI)| 1.00 (Ref.) | 1.81 (1.08–3.03) | 0.024   |
| Additionally adjusted for Oncology patients | 1.00 (Ref.) | 1.85 (1.09–3.14) | 0.023   |

*Creatinine change (%) = [(creatinine at nephrology consultation - Basal creatinine)/Basal creatinine] × 100

†Adjusted for age, sex, Liano scoring, Karnofsky scoring, prior food intake, chronic renal failure, diabetes, treatment of acute renal failure, causes of acute renal failure, community-acquired acute renal failure, basal hemoglobin, basal serum albumin, and RIFLE classes.

### Table 3: Odds Ratio (ORs) and (95% confidence intervals) for in-hospital mortality; according to the increased percentage of creatinine with respect to basal creatinine

| GROUPS OF % CREATININE INCREASE | < 101% increment | ≥ 101% increment | p value |
|----------------------------------|------------------|------------------|---------|
| Creatinine and mortality n       | 56               | 102              |         |
| Incidence of in-hospital mortality, n (%) | 26 (46.4) | 64 (62.7) |         |
| Odds Ratios                      |                  |                  |         |
| Crude OR (95% CI)                | 1.00 (Ref.)      | 1.94 (1.00–3.76) | < 0.001 |
| Age- and sex-adjusted OR (95% CI)| 1.00 (Ref.)      | 2.01 (1.03–3.92) | 0.040   |
| Multivariate-adjusted OR† (95% CI)| 1.00 (Ref.) | 2.66 (1.00–7.21) | 0.050   |
| Additionally adjusted for Oncology patients | 1.00 (Ref.) | 2.88 (1.03–8.09) | 0.044   |

*Creatinine change (%) = [(creatinine at nephrology consultation - Basal creatinine)/Basal creatinine] × 100

†Adjusted for age, sex, Liano scoring, Karnofsky scoring, prior food intake, chronic renal failure, diabetes, treatment of acute renal failure, causes of acute renal failure, community-acquired acute renal failure, basal hemoglobin, basal serum albumin, and RIFLE classes.

### Discussion

This longitudinal study shows that a relative increase in baseline serum creatinine by ≥ 101% compared with the levels measured at the time of nephrology consultation is an independent predictor of mortality. Such an increase was also associated with worse functional renal recovery irrespective of the degree of ARF severity or presence of comorbid illnesses.

Due to the heterogeneous nature of ARF [11], it was important to adjust for the severity of illness with Liano score, and for the acute kidney injury with the RIFLE criteria. We have chosen the Liano score because of its ability to discriminate mortality from survival and its ability to calibrate the observed mortality rate with the expected mortality in ARF [11,14,27]. The RIFLE consensus criteria gives a standard definition and a level of classification of severity in ARF [20], a request often made by the experts [6,18,19]. Working in this manner may allow continuing further investigation in ARF, and is one of the main strengths of this study. Patients did not do worse because...
they had more severe ARF or comorbid illnesses. Instead, patients presenting the same RIFLE criteria and Liano scores, but with higher serum creatinine increments prior to the nephrology consultation, showed higher mortality rates.

Using multivariate logistic regression analysis, we found that an increment in creatinine with respect to baseline level of 101% at the time of nephrology consultation started is a factor independently and strongly predictive of death in this cohort. Doubling the basal creatinine level presented an odds ratio of 1.81 for mortality among general population. This increased to a threefold (OR = 2.66) mortality in patients who needed continuous renal replacement therapy. These results might suggest that the increase of serum creatinine level at the moment when the ARF began to be treated by an expert was related to the outcome. However, we should concede the possibility that the more abrupt increase in serum creatinine was, the worse the prognosis. Because of the observational nature of the present study, our findings need to be interpreted with caution. We cannot determine with certainty that finding a higher increase in the percentage of creatinine was a consequence of a delayed nephrology consultation. It could be that among patients who received the nephrology intervention at the same time, some of them presented a higher increase in the percentage of creatinine because of an abrupt deterioration of renal function. Nevertheless, after adjusting for severity of ARF and comorbid illnesses, patients who had had higher increments in percentage of creatinine prior to being treated by a nephrologist did present higher mortality rates. We might stand for prompt expert consultation because these ARF patients at risk would benefit from an intensive and specialized treatment, and further kidney damage could be minimized.

The cohort included a heterogeneous distribution of patients, in terms of unit, nature, or source of admission; but with an important number of oncology patients (35.4%) since our institution is a well-known center in Spain for the treatment of oncologic diseases. For this reason, we adjusted adding the oncology factor to the logistic regression in an extra analysis. However, because of its longitudinal design, we could obviate the Berkson bias (to take a falsely typical population of patients since the group of people being studied has no form of control over whether to participate) [28]. Also, it could be argued that this was a single center study, with its limits to apply to other hospitals. We have tried to minimize any bias using objective data collected by a single investigator following

---

**Table 4:** Estimates (regression coefficients and 95% confidence intervals) for the subsequent outcome in % creatinine* (mg/dL) at discharge from hospital according to increased percentage of creatinine † with respect to basal creatinine

| GROUPS OF % CREATININE INCREASE |  < 101% increment | ≥ 101% increment | p value |
|---------------------------------|------------------|-----------------|--------|
| Creatinine n                    | 250              | 208             |        |
| Absolute Creatinine change*     |                  |                 |        |
| %, mean (95% CI)                | (29.46–46.47)    | (83.79–145.65)  |        |

| Differences in Creatinine change |                  |
|---------------------------------|------------------|
| Crude (Regression coefficient, β) | 0 (Ref.) +76.76 (+47.14 to +106.38) | < 0.001 |
| Age- sex-adjusted (Regression coefficient, β) | 0 (Ref.) +71.27 (+41.78 to +100.77) | < 0.001 |
| Multivariate adjusted model‡ (Regression coefficient, β) | 0 (Ref.) +48.92 (+13.05 to +84.79) | 0.008 |
| Additionally adjusted for Oncology patients | 0 (Ref.) +49.93 (+14.02 to +85.83) | 0.007 |

---

*Creatinine change (%) = [(creatinine at nephrology discharge - Basal creatinine) / Basal creatinine] × 100
†Creatinine change (%) = [(creatinine at hospital consultation - Basal creatinine) / Basal creatinine] × 100
‡Adjusted for age, sex, Liano scoring, Karnofsky scoring, prior food intake, chronic renal failure, diabetes, treatment of acute renal failure, causes of acute renal failure, community-acquired acute renal failure, basal hemoglobin, basal serum albumin, and RIFLE classes.

---

**Figure 1** Six-month survival after starting the nephrology consultation according to increase creatinine percentage*.
strict criteria, and reviewing the data. Urine output data were not available; therefore it was not possible to estimate the RIFE criteria according to this value. We started to collect the data before the RIFE criteria was formulated, and most of the ward patients had no urine output measured on a six hourly basis. We assume that we might underestimate some cases according to the RIFE criteria; but only 21 and 62 patients from groups R and I respectively had oliguria. Although we cannot rule out the possibility of residual confounding, it is unlikely that it can fully explain the observed strong associations. Moreover, when we adjusted for RIFE criteria, an increase of our estimations occurred in the multivariate model; so misclassification of this covariate would most likely bias the odds ratios toward the null value.

We calculated the MDRD equation to obtain a baseline serum creatinine in patients with no previous history of renal failure because a true baseline is often unknown. We solved the equation assuming a GFR of 75 ml/minute/1.73 m², which has been reported to estimate a lower limit of a normal GFR [4,13,20]. Because GFR was assumed to be 75 ml/min, using MDRD for patients with unknown pre-morbid renal dysfunction may underestimate severity of ARF according to the RIFE criteria [29,30]. This lack of reliability is one of the controversial issues regarding the RIFE criteria, but it is still unresolved [31]. Although the MDRD formula may be less accurate at normal GFR, resulting in overdiagnosis of ARF, it should not be a disadvantage in a clinical setting where ARF is taken seriously, and the MDRD also has the advantage of not requiring body weight data [32] that could be wrongly estimated in fluid retention settings.

We chose to calculate the percentage change in creatinine respect to its baseline because serum creatinine is modulated by muscle bulk. Therefore, smaller changes as 0.3 or 0.5 mg/dl will have distinct significance for patients with different genders and/or ages, whose normal baseline levels are different [18]. For this reason, we found that a relative increase in creatinine was more accurate than an absolute increase one.

The higher presence of chronic renal failure in the < 101% increment group might be explained because concern about it could have induced earlier nephrology consultation, even if the patient did not present signs of ARF in that time. However, we must admit that 74 chronic renal failure patients (48.68%) might have presented an unstable serum creatinine value at hospital admission, thus underestimating the severity of ARF for them. Chronic renal failure was included in this study to represent the common clinical practice, and thereafter it was adjusted for in the analysis because of expecting different outcomes than the general population.

On the other hand, the higher proportion of cases of ARF developed in the community in the ≥ 101% increase group might suggest that nephrology consultation may have been delayed because of time spent before hospital admittance, giving serum creatinine an extra time to reach a higher value.

Our results about mortality in the Renal Replacement Therapy sub-group are consistent with previously reported [9,33,34], and it is of interest the higher mortality rate in patients in the ≥ 101% increase group. What we may learn here is that this group of patients is most likely to benefit from a more intensive treatment.

The degree of renal injury is likely to affect renal recovery. Patients where consultation was started with ≥ 101% creatinine increase had significant higher creatinine levels at discharge compared to their baseline levels, and many of them would be expected to develop chronic renal malfunction. Adjustment for confounding factors in the analysis was done, too.

We analyzed 6-months mortality separately, since the time when patients are discharged from hospital might vary between admission units. Although it could be argued that all-cause mortality at six months is non-specific, we found that a high number of deaths (175) occurred in the first 60 days. These findings agree with previous reports and recommendations about optimal follow-up time in patients with established ARF [20,26,35].

It is of interest to note that 306 patients from the original population of 1008 would not have been diagnosed of ARF had the RIFE criteria been used then. They did not present oliguria nor enough creatinine increment, but ARF had the RIFE criteria been used then. They did not present oliguria nor enough creatinine increment, but were diagnosed of ARF according to another criteria at that time. Some experts might prefer to use more inclusive criteria because of concern about under-recognizing ARF [6].

Finally, had our patients presented other mortality rates, if they would have been treated by a nephrologist before reaching serum creatinine levels more than twice their baseline levels, is a question beyond this study and needs further research.

**Conclusion**

At the same degree of severity of kidney injury and comorbid illnesses, while controlling for other potential confounders, ARF patients with a relative increase of ≥ 101% in the baseline creatinine at the time of the nephrology consultation was an independent predictor of mortality and worse prognosis. The calculation of relative serum creatinine increase could be used as a precise and useful
input from all authors. The final version was approved by all authors.

Acknowledgements
The authors wish to express their gratitude for the contributions made by Dr. Anatole S. Menon Johansson and Dr Zubair Kabir.

References
1. Abassof NY, Tolba YA, Heap M, Russell J, El Nahas AM: The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis 2005, 46(6):1038-1048.
2. Hegarty J, Middleton RJ, Krebs M, Hussain H, Cheung C, Ledson T, Hutchinson AJ, Kalra PA, Rayner HC, Stevens PE, et al.: Severe acute renal failure in adults: place of care, incidence and outcomes. QM 2005, 98(9):661-666.
3. Herrerra-Gutierrez ME, Seller-Perez G, Maynar-Moliner J, Sanchez-Izquierdo-Riera JA: [Epidemiology of acute kidney failure in Spanish ICU. Multicenter prospective study FRAM]. Med Intensiva 2006, 30(6):260-267.
4. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006, 10(3):R73.
5. Levy EM, Wiscoll CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996, 275(19):1498-1494.
6. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11(2):R31.
7. Mehta RL, McDonald B, Gabbai F, Pahl M, Farkas A, Pascual MT, Zhuang S, Kaplan RM, Chertow GM: Nephrology consultation in acute renal failure: does timing matter? Am J Med 2002, 113(6):456-461.
8. Metcalfe W, Simpson M, Khan IH, Prescott GJ, Simpson K, Smith WC, MacLeod AM: Acute renal failure requiring renal replacement therapy: incidence and outcome. QJM 2002, 95(9):579-583.
9. Mehta RL, Pascual MT, Soroko S, Chertow GM: Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Critical care medicine 2002, 30(9):2051-2058.
10. Mozziconacci P AM, Loirat P, et al.: Comparison of SAPS, APACHE II and OSF in the evaluation of severe acute renal failure. Intensive care medicine 1992, 18(suppl):565-70.
11. Star RA: Treatment of acute renal failure. Kidney international 1998, 54(6):1817-1831.
12. Uchino S: The epidemiology of acute renal failure in the world. Curr Opin Crit Care 2006, 12(6):538-543.
13. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C: An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Critical care medicine 2006, 34(7):1913-1917.
14. Uchino S, Bellomo R, Morimatsu H, Morgera S, Scheetz M, Tan L, Bouman C, Macedo E, Gibney N, Tolwani A, et al: External validation of severity scoring systems for acute renal failure using a multinational database. Critical care medicine 2005, 33(9):1961-1967.
15. Stevens PE, Tamimi NA, Al-Hassani MK, Mikhail AI, Kearney E, Lapworth R, Prosser DI, Carmichael P: Non-specialist management of acute renal failure. QM 2001, 94(10):533-540.
16. Mehta RL, Pascual MT, Soroko S, Chertow GM: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002, 288(20):2547-2553.
17. Hilton R: Acute renal failure. BMJ (Clinical research ed 2006, 333(7572):786-790.
18. Bellomo R, Kellum J, Ronco C: Acute renal failure: time for consensus. Intensive care medicine 2001, 27(1):1685-1688.
19. Kellum JA, Levin N, Bouman C, Laneirme N: Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002, 8(6):509-514.
20. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8(4):R204-212.

Key messages
1. Acute renal failure is a condition with a high risk of mortality.
2. At the same degree of acute renal failure and comorbid illnesses severity, and receiving similar treatment, patients who had presented an increment of creatinine ≥ 101% with respect to baseline at the time of nephrology consultation showed increased mortality rates.
3. Those patients were discharged from hospital with more deteriorated renal function.
4. The calculation of relative serum creatinine increase might be used as a precise and useful tool in the general medical practice. Predicting the outcome helps to identify those patients who would benefit from a intensive therapy, and also to reassure patients and their relatives.

Abbreviations
ARF: Acute Renal Failure.
RIFLE: Risk, Injury, Failure, Loss, End Stage Classification for acute kidney injury.
ADQI: Acute Dialysis Quality Initiative.
GFR: Glomerular Filtration Rate.
AKIN: Acute Kidney Injury Network.
MDRD: Modification of Diet in Renal Disease
OR: Odds Ratio.
CI: Confidence Intervals.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
All the authors conceived the research question. JRPV and MBR wrote the first draft and conducted the statistical analysis with advice from JdI, PM and JL. PM and JL coordinated the research. JL contributed to data collection. Subsequent revisions were carried by JRPV and MBR with
21. Liano F, Gallego A, Pascual J, Garcia-Martín F, Teruel JL, Marcen R, Orofino L, Orte L, Rivera M, Gallego N, et al.: Prognosis of acute tubular necrosis: an extended prospectively contrasted study. Nephron 1993, 63(1):21-31.
22. Brochner-Mortensen J: Current status on assessment and measurement of glomerular filtration rate. Clin Physiol 1985, 5(1):1-17.
23. Dondi M, Fanti S: Determination of individual renal function through noninvasive methodologies. Curr Opin Nephrol Hypertens 1995, 4(6):520-524.
24. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266.
25. Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984, 53(9):2002-2007.
26. Palevsky PM, Meinitz PG, Piccinni P, Vinsonneau C: Selection of endpoints for clinical trials of acute renal failure in critically ill patients. Curr Opin Crit Care 2002, 8(6):S15-518.
27. Douma CE, Redekop WK, van der Meulen JH, van Olden RW, Haeck J, Struijk DG, Krediet RT: Predicting mortality in intensive care patients with acute renal failure treated with dialysis. J Am Soc Nephrol 1997, 8(1):111-117.
28. De Irala J, Martinez-Gonzalez MA: Errores en la estimación en estudios epidemiológicos (Mistakes in epidemiological estimations). In Epidemiología aplicada Edited by: De Irala JM-GMA, Segui-Gomez M. Barcelona: Ariel S.A.; 2004:266.
29. Maccariello E, Soares M, Valente C, Nogueira L, Valenca RV, Machado JE, Rocha E: RIFLE classification in patients with acute kidney injury in need of renal replacement therapy. Intensive care medicine 2007, 33(4):597-605.
30. Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, Hall PM: Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005, 46(2):242-252.
31. Joannidis M: Classification of acute kidney injury: are we there yet? Intensive care medicine 2007, 33(4):572-574.
32. Lameire N, Adam A, Becker CR, Davidson C, McCullough PA, Stacul F, Tumlin J: Baseline renal function screening. The American journal of cardiology 2006, 98(6A):21K-26K.
33. Liano G, Pascual J: Acute renal failure. Madrid AcuteRenal Failure Study Group. Lancet 1996, 347(8999):479, author reply 479
34. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, et al.: Acute renal failure in critically ill patients: a multinational, multicenter study. Jama 2005, 294(7):813-818.
35. Bell M, Liljestam E, Granath F, Frycksstedt J, Ekboon A, Martling CR: Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. Nephrol Dial Transplant 2005, 20(2):354-360.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2369/8/14/prepub